Prelude Therapeutics (PRLD) Profit After Tax (2019 - 2026)

Prelude Therapeutics has reported Profit After Tax for 8 years, with the latest figure at -$10.4 million in Q1 2026.

• Quarterly Profit After Tax rose 67.5% year-over-year to -$10.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$77.8 million (up 39.23% YoY) and the FY2025 annual result came in at -$99.5 million, up 21.88% from the prior year.
• Profit After Tax rose to -$10.4 million in Q1 2026 per PRLD's latest filing, from -$16.4 million in the prior quarter.
• Over five years, Profit After Tax peaked at -$10.4 million in Q1 2026 and troughed at -$34.7 million in Q2 2024.
• A 5-year average of -$27.8 million and a median of -$30.0 million in 2022 frame the typical range for Profit After Tax.
• The sharpest annual moves came in 2022 and 2026: Profit After Tax sank 38.33% in 2022, then soared 67.5% in 2026.
• Over 5 years, Profit After Tax stood at -$28.0 million in 2022, then retreated by 15.29% to -$32.2 million in 2023, then gained by 10.32% to -$28.9 million in 2024, then soared by 43.21% to -$16.4 million in 2025, then jumped by 36.47% to -$10.4 million in 2026.
• According to Business Quant data, Profit After Tax over the past three periods registered -$10.4 million, -$16.4 million, and -$19.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.